Virinchi Ltd Reports Rs 8.10 Crore Loss in Q4; Revenue Up 16.55%

TECHNOLOGY
Whalesbook Corporate News Logo
AuthorAarav Shah|Published at:
Virinchi Ltd Reports Rs 8.10 Crore Loss in Q4; Revenue Up 16.55%
Overview

Virinchi Limited reported a Q4 standalone loss of Rs. 8.10 crore, largely due to a Rs. 8.43 crore one-time write-off. Despite this, revenue grew 16.55% to Rs. 44.45 crore. The company highlighted promoter capital infusion in its healthcare arm and expects FY27 to be stronger.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Virinchi Ltd Posts Q4 Loss on One-Time Write-off, Revenue Grows

Virinchi Limited reported a standalone net loss of Rs. 8.10 crore for the fourth quarter of FY2026. Revenue for the quarter increased by 16.55% to Rs. 44.45 crore compared to the previous year.

Reader Takeaway: Revenue growth is positive, but the significant write-off impacted quarterly profit.

What just happened

Virinchi Limited announced its audited financial results for the fourth quarter and full fiscal year 2026. The company posted a standalone net loss of Rs. 8.10 crore for Q4FY26, a significant drop from a profit of Rs. 1.71 crore in Q4FY25. This loss was heavily influenced by a one-time, fully provided bad-debt write-off of Rs. 8.43 crore related to a major SaaS customer, QC Holdings.

Despite the bottom-line hit, standalone revenue for the quarter saw a healthy increase of 16.55%, reaching Rs. 44.45 crore, up from Rs. 38.14 crore in the prior year period. EBITDA, however, declined by 61.94% to Rs. 8.78 crore due to the write-off.

Why this matters

The substantial one-time write-off significantly skewed the quarterly profitability, masking the underlying operational performance. Investors will be keen to understand the sustainability of revenue growth and the impact of the company's strategic adjustments in its IT services and healthcare segments. The promoter's capital infusion signals confidence in the healthcare subsidiary's future.

The backstory

Virinchi Limited operates across multiple business verticals including SaaS, IDC & IT Services, and Healthcare. The company has been navigating challenges in the IT services sector, particularly concerning U.S. visa regulations impacting onshore revenue. The recent promoter action to infuse capital into the healthcare subsidiary aims to bolster its development and turnaround its performance.

What changes now

The company expects a stronger performance in FY2027, driven by structural improvements and ongoing business strategies. Key focus areas will be the successful transition to offshore delivery models in IT services to mitigate margin pressures and the anticipated turnaround in the healthcare business under new leadership.

Risks to watch

The primary risk highlighted is the external pressure on the IT services segment due to the U.S. visa regime, which could continue to affect billing rates and revenue. The impact of the one-time write-off on future collections and overall financial health also remains a point of attention.

Peer comparison

While specific peer financial data for Q4FY26 is not provided in the filing, companies in the IT services sector are generally grappling with similar challenges related to global economic conditions and visa policies. The SaaS segment's performance with recurring revenue is a common strategy for stability across the industry.

Context metrics (time-bound)

  • Q4FY26 Standalone Revenue: Rs. 44.45 crore (up 16.55% YoY)
  • Q4FY26 Standalone PAT: Rs. -8.10 crore (Loss)
  • Q4FY26 Bad-debt write-off: Rs. 8.43 crore
  • SaaS Revenue (Q4FY26): Rs. 36.94 crore (up 6.67%)
  • Healthcare Revenue (Q4FY26): Rs. 14.49 crore

What to track next

Investors should closely monitor Virinchi Limited's progress in its IT services offshore transition, the turnaround of its healthcare business following the promoter's capital infusion, and the company's ability to maintain revenue growth without the drag of exceptional items in future quarters.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.